Grace Therapeutics (GRCE) Competitors $2.92 +0.07 (+2.46%) As of 06/12/2025 03:17 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. KRRO, EXOZ, CRDL, BHST, ATOS, IVVD, CABA, LXEO, CRBP, and CTNMShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Korro Bio (KRRO), Exozymes (EXOZ), Cardiol Therapeutics (CRDL), BioHarvest Sciences (BHST), Atossa Therapeutics (ATOS), Invivyd (IVVD), Cabaletta Bio (CABA), Lexeo Therapeutics (LXEO), Corbus Pharmaceuticals (CRBP), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Korro Bio Exozymes Cardiol Therapeutics BioHarvest Sciences Atossa Therapeutics Invivyd Cabaletta Bio Lexeo Therapeutics Corbus Pharmaceuticals Contineum Therapeutics Grace Therapeutics (NASDAQ:GRCE) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Does the media favor GRCE or KRRO? In the previous week, Korro Bio had 5 more articles in the media than Grace Therapeutics. MarketBeat recorded 6 mentions for Korro Bio and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Korro Bio's score of 1.14 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Grace Therapeutics Very Positive Korro Bio Positive Is GRCE or KRRO more profitable? Grace Therapeutics' return on equity of -20.10% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.10% -17.10% Korro Bio N/A -50.25%-38.48% Do institutionals & insiders have more ownership in GRCE or KRRO? 6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 13.5% of Grace Therapeutics shares are held by company insiders. Comparatively, 4.6% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in GRCE or KRRO? Korro Bio received 30 more outperform votes than Grace Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformGrace TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesKorro BioOutperform Votes32100.00% Underperform VotesNo Votes Which has more risk and volatility, GRCE or KRRO? Grace Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Do analysts rate GRCE or KRRO? Grace Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 310.96%. Korro Bio has a consensus price target of $102.43, indicating a potential upside of 632.68%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has stronger valuation & earnings, GRCE or KRRO? Grace Therapeutics has higher earnings, but lower revenue than Korro Bio. Grace Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$12.85M-$1.16-2.52Korro Bio$4.82M27.23-$81.17M-$9.44-1.48 SummaryKorro Bio beats Grace Therapeutics on 10 of the 16 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.61M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-2.528.6727.2119.96Price / SalesN/A262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book0.576.597.074.69Net Income-$12.85M$143.75M$3.23B$248.14M7 Day Performance-1.68%0.68%0.68%0.91%1 Month Performance12.31%11.93%9.59%5.71%1 Year PerformanceN/A4.33%32.02%14.71% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.7005 of 5 stars$2.92+2.5%$12.00+311.0%N/A$29.61MN/A-2.52N/AUpcoming EarningsKRROKorro Bio3.5574 of 5 stars$12.35+4.0%$102.43+729.4%-67.2%$115.98M$4.82M-1.3170Positive NewsAnalyst RevisionEXOZExozymesN/A$13.68+0.6%N/AN/A$114.47MN/A0.0029CRDLCardiol Therapeutics2.2673 of 5 stars$1.38-4.8%$8.67+528.0%-51.5%$114MN/A-3.5420Gap DownBHSTBioHarvest SciencesN/A$6.88-1.1%$13.67+98.6%N/A$113.00M$27.70M-5.51N/AGap DownATOSAtossa Therapeutics1.6297 of 5 stars$0.86+0.3%$6.08+607.5%-32.6%$111.06MN/A-3.918IVVDInvivyd3.8246 of 5 stars$0.93-4.5%$5.85+532.4%-48.7%$110.98M$36.69M-0.47100Positive NewsGap DownCABACabaletta Bio2.9015 of 5 stars$2.18-1.4%$20.33+832.7%-85.2%$110.62MN/A-1.0150Trending NewsAnalyst ForecastAnalyst RevisionLXEOLexeo Therapeutics3.777 of 5 stars$3.27+5.5%$18.50+465.7%-77.5%$108.55M$650K-1.0358CRBPCorbus Pharmaceuticals4.138 of 5 stars$8.80+3.9%$50.88+478.1%-82.1%$107.69MN/A-1.8840Positive NewsCTNMContineum Therapeutics2.5898 of 5 stars$4.15-5.9%$22.50+442.2%-72.2%$107.37M$50M-2.1131Positive NewsGap Up Related Companies and Tools Related Companies Korro Bio Alternatives Exozymes Alternatives Cardiol Therapeutics Alternatives BioHarvest Sciences Alternatives Atossa Therapeutics Alternatives Invivyd Alternatives Cabaletta Bio Alternatives Lexeo Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Contineum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRCE Stock Free GRCE Stock Alerts